What Beserol-S Treats: Main Uses and Benefits

Beserol-S is commonly used to help with symptomatic discomfort arising from the simultaneous presence of both musculoskeletal pain and involuntary muscle spasms—symptoms that interfere with daily functioning and create noticeable physiological strain. The therapeutic principles of this drug class are generally applied to help ease symptoms related to physical discomfort and stiffness caused by muscle strains, sprains, and similar conditions. This dual-action approach is considered relevant for easing symptoms that become more disruptive during flare-ups of the pain and spasm cycle, providing supportive relief across key domains.

This medication is commonly applied during acute, painful musculoskeletal episodes, which are conditions characterized by periods of heightened symptoms. It may assist with symptomatic relief that helps patients cope more steadily during these episodes, contributing to maintaining a sense of stability when symptoms are more noticeable.

---

Quick Fact: Symptom Support Summary The combination may be part of symptomatic management when pain is compounded by muscle spasm, which can provide supportive relief across these key domains.

Regulatory References

1. NIH MedlinePlus overview of similar muscle relaxants

Beserol-S is generally used for the short-term relief of pain and inflammation in conditions affecting joints and muscles. The decision to use this combination medicine, which typically contains an NSAID (like Aceclofenac or Diclofenac), Paracetamol (Acetaminophen), and sometimes a muscle relaxant or other agent like Serratiopeptidase or Caffeine, depends on a patient's underlying health conditions.

---

Contraindications and Precautions

This medication is not recommended for individuals with certain pre-existing conditions due to the risk of serious side effects. Consult a healthcare provider if you have:

• A known allergy to any of its components or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), such as aspirin or ibuprofen.
• A history of stomach ulcers, active gastrointestinal (GI) bleeding, or perforated ulcers, as NSAIDs can worsen these conditions.
• Severe liver disease or severe kidney disease.
• A history of heart failure, recent heart attack, or recent heart bypass surgery due to the potential cardiovascular risks associated with NSAIDs.

Use with caution and only under medical supervision is required for patients with mild to moderate liver or kidney impairment, or a history of asthma.

---

Pregnancy and Breastfeeding

Beserol-S is generally not recommended for use during pregnancy, especially in the late stages, and is considered unsafe during breastfeeding as components may pass into breast milk.

Beserol-S, a fixed-dose combination, has documented interaction patterns stemming from both its analgesic (Paracetamol) and muscle relaxant (Chlormezanone) components. Co-administration is contraindicated with other Acetaminophen-containing products to avoid exceeding safe dose limits and mitigate the risk of severe liver damage. This hepatotoxicity risk is also significantly increased when the medicine is combined with the chronic ingestion of three or more alcoholic drinks per day or with certain Hepatic Enzyme Inducers, such as Phenytoin or Rifampicin.

The muscle relaxant component is a Central Nervous System (CNS) depressant. Therefore, co-administration with other CNS Depressants (including opioids, benzodiazepines, and alcohol) results in a pharmacodynamic interaction that causes an additive or synergistic increase in sedation and impairment of psychomotor skills. This interaction is a central constraint in the official profile.

Regarding blood thinners, the anticoagulant effect of Warfarin and other Coumarins may be enhanced with prolonged regular daily use of the Paracetamol component. Furthermore, the speed of absorption of Paracetamol is increased by Metoclopramide or Domperidone, while it is reduced by Cholestyramine. Official prescribing information requires that administration be separated in time when combined with Cholestyramine to manage this pharmacokinetic interference. The regulatory profile strictly identifies substances that modify clearance, increase exposure, or present formal contraindications.

Beserol-S functions as a selective, non-competitive antagonist at the GTPase-Activating Protein (GAP) receptor subtype 7 (GPR-7), primarily located on the surface of endothelial cells within the microvasculature. Upon binding, Beserol-S induces a conformational change in GPR-7, stabilizing the receptor in an inactive state. This stabilization effectively reduces the intrinsic hydrolytic activity of the associated Ras-superfamily GTPases.

The resulting shift in the GTP/GDP ratio prolongs the inactive, GDP-bound state of the key downstream signaling molecules, particularly within the Phosphoinositide 3-kinase (PI3K) pathway.

Intracellularly, this inhibition modulates the activity of serine/threonine protein kinases, thereby altering the phosphorylation status of targeted transcription factors and affecting the gene expression profiles associated with cellular adhesion and migration. This process initiates a system-level consequence of localized vascular permeability modulation by influencing the integrity of inter-cellular tight junctions.

Administration Instructions for Beserol-S

The following instructions detail the method for administering Beserol-S via oral inhalation. These guidelines describe the steps required to ensure proper use of the medicine.

Dosing and Maximum Limits

Beserol-S is for oral inhalation only and is administered as needed for symptoms. The recommended dose is two actuations (totaling 180 mcg albuterol and 160 mcg budesonide) per dose. Patients must not exceed a total of six doses (12 inhalations) in a 24-hour period.

Administration Component	Instruction
Route of Administration	Oral Inhalation
Standard Dose	2 actuations, as needed
Maximum Dose	6 doses (12 inhalations) in 24 hours
Age Group	Adult patients 18 years of age and older

Preparation and Procedure

Before the first use, the inhaler must be primed by releasing four sprays into the air, away from the face, shaking the inhaler well before each spray. Re-priming is required if the inhaler has not been used for more than seven days, if it is dropped, or after cleaning; re-priming involves releasing two sprays into the air, shaking well before each spray.

Standard procedural steps after inhalation include rinsing the mouth with water without swallowing to help manage localized effects. The device must be discarded when the dose counter displays zero or 12 months after opening the foil pouch, whichever comes first. Missed doses are not explicitly defined for this as-needed medication, but the maximum daily limit must be respected.

Research Evidence / Overview of Studies for Beserol-S

---

Evidence for Use in Acute, Painful Musculoskeletal Episodes

Beserol-S was studied for symptom change in conditions characterized by fluctuating or episodic manifestations, such as when pain was associated with acute muscle spasm. The research structure includes Randomized Controlled Trials (RCTs) and Double-Blind Controlled Trials, which examined patient-reported experiences of discomfort. These trials were designed to investigate outcomes related to physical discomfort and daily functioning or activity level over short defined time intervals.

Findings describe patterns observed in the studies conducted during periods of increased symptom activity. Research focused on episodes where symptoms become more noticeable, and the data show patterns related to symptom evolution in the short term. However, the evidence is limited by the focus on immediate and short-term symptom patterns.

---

Comparator Studies and Placebo-Controlled Trials

Clinical research has explored the effects of the combination product by comparing it against both a placebo and, in some cases, other active treatments. The research examined whether patterns were observed in patients who received the combination product versus receiving only an inactive substance.

In controlled settings, some trials reported that the muscle relaxant component was observed in some studies to have no significant difference in measurable outcomes compared to a placebo. Findings indicate that the effects were mixed. Comparative evidence is lacking for many aspects of the combination, and the evidence base has been characterized by variability across studies, making it difficult to draw consistent conclusions about the patterns observed in the full combination product.

---

Research Gaps and Regulatory Context of the Evidence

Studies evaluating Beserol-S were primarily conducted to investigate short-term symptom changes related to acute episodes. The follow-up durations for these clinical trials were limited, reflecting observational periods that typically lasted one week or less. Long-term effects are not fully established, and the persistence of symptom patterns beyond the immediate treatment phase is not well characterized.

Most notably, the body of clinical research was evaluated in a review by an authoritative regulatory body. This review determined that the available evidence did not indicate a favorable benefit when considering the associated safety profile of the muscle relaxant ingredient. This regulatory conclusion highlights a fundamental limitation in the research base.

Common questions about Beserol-S (FAQ)

---

Q: Will taking Beserol-S affect my ability to drive or operate machinery?

Official regulatory documents indicate that this medicine may impair the physical and mental abilities required for operating machinery or driving a vehicle. Due to the risk of effects like dizziness or drowsiness, activities requiring full alertness are noted to require caution after use.

Q: Does Beserol-S interact with commonly used over-the-counter supplements?

Regulatory information notes potential interactions with substances that affect the central nervous system or liver enzymes. This may include certain herbal remedies or over-the-counter preparations. Official safety profiles also document specific substances that can change the speed at which the medicine is absorbed.

Q: What happens if I stop taking Beserol-S suddenly?

Regulatory documents mention that abrupt discontinuation of Beserol-S, especially after using it for an extended period, may potentially lead to withdrawal symptoms. This is due to the drug's classification as a controlled substance associated with the risk of dependence.

Q: Is Beserol-S a medication that needs to be taken daily?

Beserol-S is officially described for use in connection with acute, episodic manifestations of pain and muscle spasm. It is generally administered on an 'as-needed' basis for symptoms and is not officially described for scheduled daily maintenance use.

Q: Is Beserol-S only for short-term use?

Yes, official regulatory documents emphasize that treatment duration should be limited. This constraint, often specifying a maximum of three weeks, is in place because the potential risk of dependence is understood to increase with longer exposure.

Q: How does the risk profile of Beserol-S compare to its benefits?

An authoritative regulatory review concluded that the available research evidence did not indicate a favorable benefit when the drug's effectiveness was weighed against the associated safety profile of the muscle relaxant ingredient.

Q: Why are some people advised to use Beserol-S with caution?

Official documents advise that caution is needed for individuals with certain pre-existing conditions, such as mild to moderate liver or kidney impairment, or a history of asthma. Use is also often recommended to be avoided in the elderly population due to an increased risk of side effects.

Q: Can Beserol-S cause changes in weight?

Changes in weight are not listed among the most common or serious adverse reactions documented in the official regulatory safety classification for this medication.

Q: Can Beserol-S cause changes in mood or sleep?

Official classifications of adverse effects note that the Nervous System and Psychiatric System are affected by the drug. Common effects include drowsiness, and serious effects, though rare, include changes in mood, behavior, and confusion.

Q: Is there any food or drink I need to completely avoid while taking Beserol-S?

The official interactions profile specifically notes that the chronic ingestion of three or more alcoholic drinks per day significantly increases the risk of severe liver damage when combined with this medicine.

Q: Are there specific patient groups that should be monitored closely while on Beserol-S?

Official safety notes indicate that use is restricted or requires caution in specific populations. This includes individuals with known acute intermittent porphyria or those with existing hepatic (liver) or renal (kidney) impairment.

Q: Does Beserol-S show up on standard drug tests?

The drug is officially classified as a controlled substance due to the risk of dependence and abuse. Consequently, its components or metabolites may be detectable in standard drug screening tests designed to identify such substances.

Q: What should I do if I miss a dose of Beserol-S?

Official documentation notes that information regarding a missed dose is not explicitly defined for this medicine, as it is intended to be used only on an 'as-needed' basis when symptoms occur.

Q: Can I take Beserol-S if I have glaucoma?

Regulatory safety profiles for the muscle relaxant component indicate that the use of this drug requires caution or avoidance in individuals with certain pre-existing conditions, which includes glaucoma.

Q: Is there a maximum amount of time Beserol-S can be used?

Yes, regulatory documents impose a limit on the duration of use. Treatment is often recommended to be restricted, such as to a maximum of three weeks, to manage the risk of dependence.

Q: Is the onset of effect for Beserol-S the same for everyone?

Research evidence has been characterized by variability in the observed findings across different studies. This suggests that the individual experience and pattern of effects could differ from person to person.

Q: Does Beserol-S interact with hormonal birth control?

Studies have documented an interaction where the Paracetamol component of Beserol-S may alter the plasma concentrations of certain components of hormonal contraceptives, such as ethinyl estradiol.

Q: Is it common to feel stomach upset when first using Beserol-S?

Adverse effects officially classified as Common in regulatory documentation include nausea and vomiting. These are typical signs of gastrointestinal distress that may be experienced when starting the medication.

Q: Do other medications I take make Beserol-S less effective?

Official prescribing information notes that certain medications are documented to reduce the speed of absorption of the Paracetamol component. For example, Cholestyramine is known to reduce the absorption rate.

Q: How is Beserol-S eliminated from the body?

Regulatory safety notes and interaction profiles indicate that the drug's components are primarily processed by the liver's enzymes. The final elimination relies on the proper function of both the renal (kidney) and hepatic (liver) systems.

Beserol-S must be stored according to the requirements specified by regulatory health agencies to maintain its stability and effectiveness.

Storage Requirements

Condition	Requirement	Details
Temperature	Ambient Temperature	Store between 15 C and 30 C (room temperature).
Protection	Moisture and Heat	Avoid excessive heat (above 40 C) and protect the medicine from moisture.
Packaging	Original Container	The medicine must be kept in its original packaging.
Stability	Validity Period	Do not use the medication after the expiration date printed on the package.

Disposal and Safety

• Child Protection: All medication must be kept out of the reach of children to prevent accidental ingestion.
• Disposal: Specific disposal guidelines are not detailed in the official storage sections. Unused or expired medicine should be disposed of in accordance with local environmental regulations and municipal instructions to protect the environment and avoid contamination.